Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
VXRT Stock: The Big FDA News Sending Vaxart Shooting Higher Today
10:42am, Monday, 02'nd Aug 2021
VXRT stock is bulking up today. The company is getting approval from the FDA regarding its Covid vaccine, allowing for further research.
Vaxart Stock Is Trading Higher As FDA Clears Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate
09:11am, Monday, 02'nd Aug 2021
The FDA has signed off Vaxart Inc's (NASDAQ: VXRT) Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. "This is great news because it allows us to move forw
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
08:00am, Monday, 02'nd Aug 2021
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2021 /PRNewswire/ -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, announced today that th
Can Last Year's Biggest Vaccine Stocks Crush the Market Again?
06:00am, Monday, 02'nd Aug 2021
These players delivered triple- and quadruple-digit gains.
Vaxart Stock Shoots Higher After Its Oral Vaccine Boosts Immune Response In Previously Vaccinated Subject
10:18am, Thursday, 29'th Jul 2021
Vaxart Inc's (NASDAQ: VXRT) has disclosed data from a 12-subject Phase 1b blinded study evaluating the ability of its oral norovirus vaccine to boost immunogenicity. Study participants were initi
VXRT Stock Increases Over 10% Pre-Market: Why It Happened
08:59am, Thursday, 29'th Jul 2021
The stock price of Vaxart Inc (NASDAQ: VXRT) increased by over 10% pre-market. This is why it happened.
Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine
08:22am, Thursday, 29'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platfo
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
01:04pm, Monday, 26'th Jul 2021
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.
Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill
06:00am, Monday, 26'th Jul 2021
You can buy VXRT stock for the company's tablet-based Covid-19 vaccine, and hold it for Vaxart's other clinical breakthroughs. The post Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill appea
Vaxart: World's First Oral COVID Vaccine In Development
08:30am, Sunday, 25'th Jul 2021
On July 22, both The Jerusalem Post and Forbes reported that Oravax Medical's oral COVID vaccine candidate is about to begin a phase 1 trial in Israel. While Israel is said to be "first in world" to t
Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain
02:45pm, Thursday, 22'nd Jul 2021
Vaxart may have a second chance at prominence with its Covid-19 vaccine pill. But VXRT stock is still a largely speculative buy.
Why Shares of Vaxart Jumped 31.2% in the First Half of 2021
06:21pm, Monday, 19'th Jul 2021
The first half has been a cycle of hope and disappointment for shareholders.
Why Coronavirus Stocks Are Zooming Higher Today
03:12pm, Monday, 19'th Jul 2021
The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.
3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street
06:06am, Thursday, 15'th Jul 2021
Analysts' high-water price targets imply some serious gains for these companies.
Don't Count on a Covid-19 Boost for Vaxart
12:40pm, Wednesday, 14'th Jul 2021
VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day. The post Don't Count on a Covid-19 Boost for Vaxart appeared first on Investor
